Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Adenosine Receptor A3 (ADORA3) - Overview
Adenosine Receptor A3 (ADORA3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development
BioIntervene Inc
Can-Fite BioPharma Ltd
Future Medicine Co Ltd
Neumentum Inc
Palo BioFarma SL
Protheragen Inc
Adenosine Receptor A3 (ADORA3) - Drug Profiles
BIO-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPP-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-1888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-2698 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
modenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTM-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-1650 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piclidenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ADORA3 for Autoimmune Disorders, Inflammation, Liver Cancer and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ADORA3 for Chronic Inflammation and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adenosine Receptor A3 (ADORA3) - Dormant Products
Adenosine Receptor A3 (ADORA3) - Discontinued Products
Adenosine Receptor A3 (ADORA3) - Product Development Milestones
Featured News & Press Releases
Jul 08, 2021: Can-Fite gears up to initiate pivotal phase III liver cancer study
Jun 16, 2021: Can-Fite receives notice of patent allowance in Chi for SH treatment
Jun 02, 2021: Can-Fite to Initiate phase IIb SH study with its drug candidate modenoson
Apr 29, 2021: Can-Fite’s phase III psoriasis study achieves 75% enrollment; top line results expected Q4 2021
Apr 22, 2021: Can-Fite expands its phase II COVID-19 study to Europe
Apr 20, 2021: Can-Fite initiates preclinical studies required by FDA and EMA for the registration of its lead drug candidate modenoson
Apr 20, 2021: Can-Fite initiates preclinical studies required by FDA and EMA for the registration of its lead drug candidate piclidenoson
Apr 05, 2021: Can-Fite: Canbis compound inhibits liver cancer growth in preclinical studies
Mar 19, 2021: Can-Fite BioPharma interview to air on bloomberg television U.S. on the RedChip Money Report
Mar 18, 2021: Can-Fite: Topical administration of CF602 fully recovers erectile dysfunction in diabetic model
Mar 08, 2021: Can-Fite BioPharma enrols first patient to study Covid-19 drug
Feb 22, 2021: New positive data from Can-Fite’s liver cancer phase II clinical study with modenoson
Feb 01, 2021: Can-Fite announces inhibition of liver fibrosis by canbis compounds in preclinical studies
Jan 28, 2021: Can-Fite’s SH indication highlighted in webir by KOL Dr. Harrison: “modenoson May Have Big Impact on SH”
Jan 08, 2021: Can-Fite announces publication of modenoson liver cancer study in peer reviewed jourl?Cancers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by BioIntervene Inc, 2021
Pipeline by Can-Fite BioPharma Ltd, 2021
Pipeline by Future Medicine Co Ltd, 2021
Pipeline by Neumentum Inc, 2021
Pipeline by Palo BioFarma SL, 2021
Pipeline by Protheragen Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021